Investigational drug · Phase 2
DSP107
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colorectal Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "DSP107"
First trial start
2020
Oct 7, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DSP107", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer
- Advanced Solid Tumor
- Non Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "DSP107" as an intervention, largest first.
- A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid TumorsPivotal-lookingActive, not recruiting
Kahr MedicalIndustry
NCT04440735 · 125 participants (planned) · Start Oct 7, 2020 · Primary completion Sep 2025
Drug: DSP107; Atezolizumab · For: Advanced Solid Tumor; Non Small Cell Lung Cancer; Colorectal Cancer
Sites: La Jolla, California; Aurora, Colorado; Lake Mary, Florida · 7 sites in all
Kahr Bio Australia Pty LtdIndustry
NCT07235293 · 90 participants (planned) · Start Jan 16, 2026 · Primary completion Sep 30, 2026
Drug: DSP107 + Atezolizumab; Fruquintinib · For: Colorectal Cancer
Sites: Aurora, Colorado; Highlands Ranch, Colorado; Florida City, Florida · 18 sites in all
- A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological MalignanciesTerminated
Kahr MedicalIndustry
NCT04937166 · 25 participants · Start Jan 13, 2022 · Primary completion Apr 23, 2025
Drug: DSP107; Azacitidine and 1 more · For: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia
Sites: Duarte, California; Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
Cendrowicz E, Jacob L, Greenwald S, et al. · J Exp Clin Cancer Res 2022
Also in development for Colorectal Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.